active times ahead ..

Plenty of companies would be satisfied having one good product to go commercial, take Cochlear the hearing aid provider it has only 1 excellent product ..SP around $59 constantly paying $2 div pa. and still has South Amer. East Europe and China as an underdeveloped market ..I believe we have many products both life saving and others that will restore excellent quality of life in various trial stages .. ..Keeping in mind neurolgy products such as stroke /parkinsons/ multiple sclerosis.are deep into pre clinicle trials , as are some inflammatory products.The 1H12 this month should update progress of ph2 trials for spinal fusion and disc repair... MSB is in negotiation with potential suitors for its T2D Teva /Sanofi-Aventis /Amgen and or others, which is great but the focus will be on quaility rather than $s..Bring it on !! Interestingly TEVA now states MSB,s cardiovascular app. was one of the major reasons why they purchased CEPH. (6.8.bill $) Cheers Vin